Výsledky vyhledávání - "H. R. Mäcke"

Molecular Oxygen, Superoxide, and Peroxide as Ligands in a CoN5 Complex

Autor: Marcel Maeder, H. R. Mäcke

Publikováno v: Inorganic Chemistry. 33:3135-3140

The cobalt(II)complex (papd)Co II (H 2 O) 2+ (papd=1,5,8,11,15-pentaazapentadecane) reacts with molecular oxygen to form a μ-peroxo complex in the traditional Wilkins reaction scheme (k 1 = 1.4×10 -7 M -1 s -1 , k -1 =0.65 s -1 , k 2 =1.210 7 M -1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72a12c208f7b0a60e9044e77e60b9ebe
https://doi.org/10.1021/ic00092a020

Zobrazit plný text záznamu

[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors]

Autor: A, Otte, R, Herrmann, H R, Mäcke, J, Müller-Brand

Publikováno v: Praxis. 88(31-32)

Current concepts for the treatment of somatostatin receptor positive tumours have not been very motivating up to now. A promising alternative could be the new peptidic vector DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC) recently developed in Basel. It may b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f3519dfa144cbba3be5fee0ceca62b2d
https://pubmed.ncbi.nlm.nih.gov/10479965

Zobrazit plný text záznamu

Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment

Autor: S, Froidevaux, E, Hintermann, M, Török, H R, Mäcke, C, Beglinger, A N, Eberle

Publikováno v: Cancer research. 59(15)

Octreotide is a somatostatin analogue that is widely used for cancer therapy and tumor imaging. Its efficacy in tumors depends mainly on the expression of the somatostatin receptor type 2 (sst 2). Desensitization and down-regulation of sst 2 after ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7c2b0bc8c16cd8ff8a6d96747376c358
https://pubmed.ncbi.nlm.nih.gov/10446977

Zobrazit plný text záznamu

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas

Autor: A, Merlo, O, Hausmann, M, Wasner, P, Steiner, A, Otte, E, Jermann, P, Freitag, J C, Reubi, J, Müller-Brand, O, Gratzl, H R, Mäcke

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(5)

Human gliomas, especially of low-grade type, have been shown to express high-affinity somatostatin receptor type 2 (J-C. Reubi et al., Am. J. Pathol, 134: 337-344, 1989). We enrolled seven low-grade and four anaplastic glioma patients in a pilot stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2aa5a23b653bfb051120ec8d36859546
https://pubmed.ncbi.nlm.nih.gov/10353735

Zobrazit plný text záznamu

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake

Autor: D J, Kwekkeboom, P P, Kooij, W H, Bakker, H R, Mäcke, E P, Krenning

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(5)

Scintigraphy with [111In-diethylenetriamine pentaacetic acid0-D-Phe1]-octreotide (DTPAOC) is used to demonstrate neuroendocrine and other somatostatin-receptor-positive tumors. Despite encouraging results, this 111In-labeled compound is not well suit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b800323df44aa72aa5e03fcd6891053
https://pubmed.ncbi.nlm.nih.gov/10319747

Zobrazit plný text záznamu

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy

Autor: M, de Jong, W A, Breeman, W H, Bakker, P P, Kooij, B F, Bernard, L J, Hofland, T J, Visser, A, Srinivasan, M A, Schmidt, J L, Erion, J E, Bugaj, H R, Mäcke, E P, Krenning

Publikováno v: Cancer research. 58(3)

We evaluated the following (111)In-labeled somatostatin (SS) analogues (diethylenetriaminepentaacetic acid, DTPA; tetraazacyclododecanetetraacetic acid, DOTA): [DTPA0]octreotide, [DTPA0,Tyr3]octreotide, [DTPA0,D-Tyr1]octreotide, [DTPA0,Tyr3]octreotat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7e79a91a04ff456ae4ef105ba5d2e038
https://pubmed.ncbi.nlm.nih.gov/9458086

Zobrazit plný text záznamu

Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy

Autor: M, De Jong, W H, Bakker, W A, Breeman, B F, Bernard, L J, Hofland, T J, Visser, A, Srinivasan, M, Schmidt, M, Béhé, H R, Mäcke, E P, Krenning

Publikováno v: International journal of cancer. 75(3)

We have evaluated the potential usefulness of radiolabelled [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide as radiopharmaceuticals for somatostatin receptor-targeted scintigraphy and radiotherapy. In vitro somatostatin receptor binding and in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1ab728c483cce512f9e143d886a12a0d
https://pubmed.ncbi.nlm.nih.gov/9455802

Zobrazit plný text záznamu

Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells

Autor: I, Novak-Hofer, H P, Amstutz, H R, Mäcke, R, Schwarzbach, K, Zimmermann, J J, Morgenthaler, P A, Schubiger

Publikováno v: Cancer research. 55(1)

Monoclonal antibody chCE7, an internalizing neuroblastoma-specific chimeric antibody, was derivatized with the macrocyclic amine ligand 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)-methyl] benzoic acid tetrahydrochloride and labeled with the potential th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5119edfaf752b9dd9413754855ef0065
https://pubmed.ncbi.nlm.nih.gov/7805039

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání